35 results on '"García-Lorenzo, Borja"'
Search Results
2. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries
- Author
-
Vallejo-Torres, Laura, García-Lorenzo, Borja, Edney, Laura Catherine, Stadhouders, Niek, Edoka, Ijeoma, Castilla-Rodríguez, Iván, García-Pérez, Lidia, Linertová, Renata, Valcárcel-Nazco, Cristina, and Karnon, Jonathan
- Published
- 2022
- Full Text
- View/download PDF
3. Performance of a rapid molecular test to detect Chlamydia trachomatis and Neisseria gonorrhoeae in women with pelvic inflammatory disease
- Author
-
Munrós, Jordina, Vergara, Andrea, Bataller, Eduardo, García-Lorenzo, Borja, Álvarez-Martínez, Miriam José, and Bosch, Jordi
- Published
- 2022
- Full Text
- View/download PDF
4. Does integrated care mean fewer hospitalizations? An evaluation of a French field experiment
- Author
-
Gaillard, Aurélie, García-Lorenzo, Borja, Renaud, Thomas, and Wittwer, Jérôme
- Published
- 2022
- Full Text
- View/download PDF
5. Disentangling the value equation: a step forward in value-based healthcare.
- Author
-
García-Lorenzo, Borja, Alayo, Itxaso, Arrospide, Arantzazu, Gorostiza, Ania, Fullaondo, Ane, and Group, VOICE Study
- Subjects
- *
SECONDARY analysis , *RESEARCH funding , *VALUE-based healthcare , *BREAST tumors , *BENCHMARKING (Management) , *CANCER patients , *EMOTIONS , *FUNCTIONAL status , *DESCRIPTIVE statistics , *PATIENT-centered care , *LUNG tumors , *PAIN , *QUALITY of life , *HEALTH outcome assessment , *SOCIODEMOGRAPHIC factors , *REGRESSION analysis - Abstract
Background The value equation of value-based healthcare (VBHC) as a single figure remains ambiguous, closer to a theoretical framework than a useful tool for decision making. The challenge lies in the way patient-centred outcomes (PCOs) might be combined to produce a single value of the numerator. This paper aims to estimate the weights of PCOs to provide a single figure in the numerator, which ultimately will allow a VBHC figure to be reached. Methods A cohort of patients diagnosed with breast cancer (n = 690) with a 6-month follow-up recruited in 2019–20 across six European hospitals was used. Patient-reported outcomes (PROs), clinical-related outcomes (CROs), and clinical and socio-demographic variables were collected. The numerator was defined as a composite indicator of the PCOs (CI-PCO), and regression analysis was applied to estimate their weights and consequently arrive at a single figure. Results Pain showed as the highest weight followed by physical functioning , emotional functioning , and ability to work , and then by a symptom, either arm or breast. PCOs weights were robust to sensitivity analysis. The CI-PCO value was found to be more informative than the health-related quality of life (HRQoL) value. Conclusions To the best of our knowledge, this is the first research to combine the PCOs proposed by ICHOM to provide a single figure in the numerator of the value equation. This figure shows a step forward in VBHC to reach a holistic benchmarking across healthcare centres and a value-based payment. This research might also be applied in other medical conditions as a methodological pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. The societal monetary value of a QALY associated with EQ-5D-3L health gains
- Author
-
Vallejo-Torres, Laura, García-Lorenzo, Borja, Rivero-Arias, Oliver, and Pinto-Prades, José Luis
- Published
- 2020
- Full Text
- View/download PDF
7. Health and economic outcomes for founding medicine on a comparable value: experiences from the VOICE Community in breast and lung cancer.
- Author
-
García-Lorenzo, Borja, primary, López de Subijana, Ania Gorostiza, additional, Alayo, Itxaso, additional, and Fullaondo-Zabala, Ane, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling
- Author
-
Dalziel, Kim, Catchpool, Max, García-Lorenzo, Borja, Gorostiza, Inigo, Norman, Richard, and Rivero-Arias, Oliver
- Published
- 2020
- Full Text
- View/download PDF
9. European value-based healthcare benchmarking: moving from theory to practice.
- Author
-
García-Lorenzo, Borja, Gorostiza, Ania, Alayo, Itxaso, Zas, Susana Castelo, Baena, Patricia Cobos, Camiña, Inés Gallego, Narbaiza, Begoña Izaguirre, Mallabiabarrena, Gaizka, Ustarroz-Aguirre, Iker, Rigabert, Alina, Balzi, William, Maltoni, Roberta, Massa, Ilaria, López, Isabel Álvarez, Lobera, Sara Arévalo, Esteban, Mónica, Calleja, Marta Fernández, Mediavilla, Jenifer Gómez, Fernández, Manuela, and Hitar, Manuel del Oro
- Subjects
- *
RESEARCH , *STATISTICAL significance , *HEALTH facilities , *HUMAN research subjects , *KEY performance indicators (Management) , *LUNG tumors , *HEALTH outcome assessment , *MEDICAL care costs , *REGRESSION analysis , *VALUE-based healthcare , *BENCHMARKING (Management) , *INFORMED consent (Medical law) , *QUESTIONNAIRES , *CLINICAL medicine , *DESCRIPTIVE statistics , *RESEARCH funding , *SOCIODEMOGRAPHIC factors , *ELECTRONIC health records , *CLUSTER analysis (Statistics) , *BREAST tumors , *LONGITUDINAL method , *DELPHI method - Abstract
Background Value-based healthcare (VBHC) is a conceptual framework to improve the value of healthcare by health, care-process and economic outcomes. Benchmarking should provide useful information to identify best practices and therefore a good instrument to improve quality across healthcare organizations. This paper aims to provide a proof-of-concept of the feasibility of an international VBHC benchmarking in breast cancer, with the ultimate aim of being used to share best practices with a data-driven approach among healthcare organizations from different health systems. Methods In the VOICE community—a European healthcare centre cluster intending to address VBHC from theory to practice—information on patient-reported, clinical-related, care-process-related and economic-related outcomes were collected. Patient archetypes were identified using clustering techniques and an indicator set following a modified Delphi was defined. Benchmarking was performed using regression models controlling for patient archetypes and socio-demographic characteristics. Results Six hundred and ninety patients from six healthcare centres were included. A set of 50 health, care-process and economic indicators was distilled for benchmarking. Statistically significant differences across sites have been found in most health outcomes, half of the care-process indicators, and all economic indicators, allowing for identifying the best and worst performers. Conclusions To the best of our knowledge, this is the first international experience providing evidence to be used with VBHC benchmarking intention. Differences in indicators across healthcare centres should be used to identify best practices and improve healthcare quality following further research. Applied methods might help to move forward with VBHC benchmarking in other medical conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Assessment of the Effectiveness, Socio-Economic Impact and Implementation of a Digital Solution for Patients with Advanced Chronic Diseases: The ADLIFE Study Protocol
- Author
-
García-Lorenzo, Borja, primary, Gorostiza, Ania, additional, González, Nerea, additional, Larrañaga, Igor, additional, Mateo-Abad, Maider, additional, Ortega-Gil, Ana, additional, Bloemeke, Janika, additional, Groene, Oliver, additional, Vergara, Itziar, additional, Mar, Javier, additional, Lim Choi Keung, Sarah N., additional, Arvanitis, Theodoros N., additional, Kaye, Rachelle, additional, Dahary Halevy, Elinor, additional, Nahir, Baraka, additional, Arndt, Fritz, additional, Dichmann Sorknæs, Anne, additional, Juul, Natassia Kamilla, additional, Lilja, Mikael, additional, Sherman, Marie Holm, additional, Laleci Erturkmen, Gokce Banu, additional, Yuksel, Mustafa, additional, Robbins, Tim, additional, Kyrou, Ioannis, additional, Randeva, Harpal, additional, Maguire, Roma, additional, McCann, Lisa, additional, Miller, Morven, additional, Moore, Margaret, additional, Connaghan, John, additional, Fullaondo, Ane, additional, Verdoy, Dolores, additional, and de Manuel Keenoy, Esteban, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Assessment of the effectiveness, socio-economic impact and implementation of a digital solution for patients with advanced chronic diseases : the ADLIFE study protocol
- Author
-
García-Lorenzo, Borja, Gorostiza, Ania, González, Nerea, Larrañaga, Igor, Mateo-Abad, Maider, Ortega-Gil, Ana, Bloemeke, Janika, Groene, Oliver, Vergara, Itziar, Mar, Javier, Lim Choi Keung, Sarah N., Arvanitis, Theodoros N., Kaye, Rachelle, Dahary Halevy, Elinor, Nahir, Baraka, Arndt, Fritz, Dichmann Sorknæs, Anne, Juul, Natassia Kamilla, Lilja, Mikael, Holm Sherman, Marie, Laleci Erturkmen, Gokce Banu, Yuksel, Mustafa, Robbins, Tim, Kyrou, Ioannis, Randeva, Harpal, Maguire, Roma, McCann, Lisa, Miller, Morven, Moore, Margaret, Connaghan, John, Fullaondo, Ane, Verdoy, Dolores, de Manuel Keenoy, Esteban, García-Lorenzo, Borja, Gorostiza, Ania, González, Nerea, Larrañaga, Igor, Mateo-Abad, Maider, Ortega-Gil, Ana, Bloemeke, Janika, Groene, Oliver, Vergara, Itziar, Mar, Javier, Lim Choi Keung, Sarah N., Arvanitis, Theodoros N., Kaye, Rachelle, Dahary Halevy, Elinor, Nahir, Baraka, Arndt, Fritz, Dichmann Sorknæs, Anne, Juul, Natassia Kamilla, Lilja, Mikael, Holm Sherman, Marie, Laleci Erturkmen, Gokce Banu, Yuksel, Mustafa, Robbins, Tim, Kyrou, Ioannis, Randeva, Harpal, Maguire, Roma, McCann, Lisa, Miller, Morven, Moore, Margaret, Connaghan, John, Fullaondo, Ane, Verdoy, Dolores, and de Manuel Keenoy, Esteban
- Abstract
Due to population ageing and medical advances, people with advanced chronic diseases (ACD) live longer. Such patients are even more likely to face either temporary or permanent reduced functional reserve, which typically further increases their healthcare resource use and the burden of care on their caregiver(s). Accordingly, these patients and their caregiver(s) may benefit from integrated supportive care provided via digitally supported interventions. This approach may either maintain or improve their quality of life, increase their independence, and optimize the healthcare resource use from early stages. ADLIFE is an EU-funded project, aiming to improve the quality of life of older people with ACD by providing integrated personalized care via a digitally enabled toolbox. Indeed, the ADLIFE toolbox is a digital solution which provides patients, caregivers, and health professionals with digitally enabled, integrated, and personalized care, supporting clinical decisions, and encouraging independence and self-management. Here we present the protocol of the ADLIFE study, which is designed to provide robust scientific evidence on the assessment of the effectiveness, socio-economic, implementation, and technology acceptance aspects of the ADLIFE intervention compared to the current standard of care (SoC) when applied in real-life settings of seven different pilot sites across six countries. A quasi-experimental trial following a multicenter, non-randomized, non-concurrent, unblinded, and controlled design will be implemented. Patients in the intervention group will receive the ADLIFE intervention, while patients in the control group will receive SoC. The assessment of the ADLIFE intervention will be conducted using a mixed-methods approach.
- Published
- 2023
- Full Text
- View/download PDF
12. Herramientas metodológicas para benchmarking en medicina basada en el valor: arquetipos y clasificación de pacientes
- Author
-
Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Biosistemak - Instituto de Investigación en Servicios de Salud, García Lorenzo, Borja, Otamendi Garitano, Maialen, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Biosistemak - Instituto de Investigación en Servicios de Salud, García Lorenzo, Borja, and Otamendi Garitano, Maialen
- Published
- 2023
13. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
- Author
-
Vallejo-Torres, Laura, García-Lorenzo, Borja, Castilla, Iván, Valcárcel-Nazco, Cristina, García-Pérez, Lidia, Linertová, Renata, Polentinos-Castro, Elena, and Serrano-Aguilar, Pedro
- Published
- 2016
- Full Text
- View/download PDF
14. WtsWrng Interim Comparative Effectiveness Evaluation and Description of the Challenges to Develop, Assess, and Introduce This Novel Digital Application in a Traditional Health System
- Author
-
Sampietro-Colom, Laura, primary, Fernandez-Barcelo, Carla, additional, Abbas, Ismail, additional, Valdasquin, Blanca, additional, Rabasseda, Nicolau, additional, García-Lorenzo, Borja, additional, Sanchez, Miquel, additional, Sans, Mireia, additional, Garcia, Noemi, additional, and Granados, Alicia, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries
- Author
-
Vallejo-Torres, Laura, primary, García-Lorenzo, Borja, additional, Edney, Laura Catherine, additional, Stadhouders, Niek, additional, Edoka, Ijeoma, additional, Castilla-Rodríguez, Iván, additional, García-Pérez, Lidia, additional, Linertová, Renata, additional, Valcárcel-Nazco, Cristina, additional, and Karnon, Jonathan, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Health Technology Assessment of a new water quality monitoring technology: Impact of automation, digitalization and remoteness in dialysis units
- Author
-
García-Lorenzo, Borja, primary, Fernández-Barceló, Carla, additional, Maduell, Francisco, additional, and Sampietro-Colom, Laura, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Evaluación de los programas para disminuir el consumo de alcohol en España: Un tema pendiente
- Author
-
García Lorenzo, Borja, Trapero Bertrán, Marta, García Lorenzo, Borja, and Trapero Bertrán, Marta
- Abstract
Background: To evaluate preventive interventions on alcohol consumption has been long recommended in Spain. The impact evaluation of structured programs and specific actions for the prevention and treatment of alcohol consumption (PAPTCA) would allow making better informed decisions on public health financing based on the efficiency criteria. To the best of our knowledge, there is no scientific document that illustrates the situation of the PAPTCAs’ evaluation in Spain. This paper aims to classify and describe PAPTCAs in Spain, focused on their impact evaluation and information on financing for accountability to society. Methods: A systematic literature review of the PAPTCAs implemented in Spain, from 2000 till 2017, at regional (autonomous communities) and local level was carried out, and a descriptive analysis of the PAPTCA database obtained from the literature review was carried out. Results: 145 structured programs and 45 specific actions were identified. Only 25% of structured programs provided an impact evaluation, besides, only 15% presented some information about their financing. Regarding the specific actions, the numbers were less encouraging where 10% provided an impact evaluation while a similar figure of PAPTCAs showed financing information. Conclusions: There is a need to systematize the information of the PAPTCA that serves as an instrument to conduct impact evaluations in Spain. This should ease the scarce presence of evaluative culture in this area and promote the accountability of resources spent on public health to society., Fundamentos: Hace tiempo que se recomienda evaluar las intervenciones preventivas en España. La evaluación del impacto de los programas estructurados y de las acciones puntuales de prevención y tratamiento del consumo de alcohol (PAPTCA) permitiría tomar las decisiones de financiación mejor informadas en materia de salud pública, desde el punto de vista de la eficiencia. No obstante, no se conoce un documento que ilustre la situación de la evaluación de los PAPTCA en España. Este artículo pretendió clasificar y describir los PAPTCA en España, prestando especial atención a la evaluación de impacto y a la información sobre financiación para la rendición de cuentas. Métodos: Se realizó una revisión bibliográfica sistematizada de los PAPTCA implementados en España tanto a nivel regional (comunidades autónomas) como local durante el periodo 2000-2017, y se llevó a cabo un análisis descriptivo de la base de datos obtenida de los PAPTCA a partir de la revisión de la bibliografía realizada. Resultados: Se identificaron 145 programas estructurados y 45 acciones puntuales. Solo el 25% de los programas estructurados evaluaron los resultados. Además, únicamente un tercio de ellos presentaron alguna información sobre su financiación. Por su parte, los números fueron menos alentadores en las acciones puntuales, donde solo el 10% evaluaron sus resultados, y una cifra similar aportó información sobre su financiación. Conclusiones: Existe una necesidad de sistematizar la información de los PAPTCA, para que sirva de instrumento en la evaluación de su impacto en España y, de esta manera, paliar la escasa presencia de cultura evaluativa en este ámbito y promover la rendición de cuentas a la sociedad de los recursos en salud pública.
- Published
- 2020
18. Cost-Effectiveness of Low-Field Intraoperative Magnetic Resonance in Glioma Surgery
- Author
-
Garcia-Garcia, Sergio, primary, García-Lorenzo, Borja, additional, Ramos, Pedro Roldan, additional, Gonzalez-Sanchez, Jose Juan, additional, Culebras, Diego, additional, Restovic, Gabriela, additional, Alcover, Estanis, additional, Pons, Imma, additional, Torales, Jorge, additional, Reyes, Luis, additional, Sampietro-Colom, Laura, additional, and Enseñat, Joaquim, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Performance of a rapid molecular test to detect Chlamydia trachomatisand Neisseria gonorrhoeaein women with pelvic inflammatory disease
- Author
-
Munrós, Jordina, Vergara, Andrea, Bataller, Eduardo, García-Lorenzo, Borja, Álvarez-Martínez, Miriam José, and Bosch, Jordi
- Abstract
The aim of this study was to investigate the prevalence of Chlamydia trachomatis(CT) and Neisseria gonorrhoeae(NG) in women with pelvic inflammatory disease (PID) and the usefulness and cost-effectiveness of a rapid molecular test for the diagnosis and clinical management of PID.
- Published
- 2022
- Full Text
- View/download PDF
20. The societal monetary value of a QALY associated with EQ-5D-3L health gains
- Author
-
Vallejo-Torres, Laura, primary, García-Lorenzo, Borja, additional, Rivero-Arias, Oliver, additional, and Pinto-Prades, José Luis, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Coste-efectividad de la vacunación contra la gripe estacional para diferentes grupos de edad: Una revisión sistemática
- Author
-
Valcárcel Nazco, Cristina, García Lorenzo, Borja, Pino Sedeño, Tasmania del, García Pérez, Lidia, Brito García, Noé, Linertová, Renata, Ferrer Rodríguez, Jorge, Imaz Iglesia, Iñaki, and Serrano Aguilar, Pedro
- Subjects
Coste-efectividad ,Influenza vaccine ,Spain ,Vacuna de la gripe ,Gripe ,España ,Revisión sistemática ,Systematic review ,Cost-effectiveness ,Influenza - Abstract
RESUMEN Fundamentos: Dada la carga económica que supone para el sistema sanitario la gripe estacional, se plantea esta revisión sistemática cuyo objetivo fue actualizar la evidencia disponible sobre el coste-efectividad de vacunación contra la gripe estacional en diferentes grupos de edad, incluyendo población infantil. Métodos: Se llevó a cabo una revisión sistemática de la literatura de evaluaciones económicas de los programas de vacunación contra la gripe estacional en niños y adultos. Se realizaron búsquedas en las bases de datos (enero 2013 - abril 2018): Medline y PREMEDLINE, EMBASE, EconLit y en las bases de datos del Centre for Reviews and Dissemination (DARE, HTA, NHS EED). Resultados: Se incluyeron 11 evaluaciones económicas. La calidad metodológica de los estudios incluidos fue buena. La evidencia científica muestra que los programas de vacunación contra la gripe estacional en niños en edad escolar pueden ser una estrategia coste-efectiva desde la perspectiva sanitaria en países europeos. La evidencia científica disponible hasta el momento no nos permite concluir que los programas de vacunación antigripal en adultos sanos de menos de 65 años de edad sean una alternativa coste-efectiva en nuestro contexto, debido a la elevada incertidumbre existente y a la escasez de estudios realizados en el contexto español. Conclusiones: Los programas de vacunación contra la gripe estacional en niños en edad escolar (3-16 años) pueden ser una estrategia coste-efectiva desde la perspectiva del SNS. ABSTRACT Background: Given the economic burden of seasonal influenza for the healthcare system, we performed a systematic review aiming to update available evidence on the cost-effectiveness of vaccination of seasonal influenza in different age groups, including children. Methods: A systematic review of the literature on economic evaluations of seasonal influenza vaccination programs in children and adults was carried out. The following databases were searched (January 2013 - April 2018): Medline and PREMEDLINE, EMBASE, EconLit and databases of the Centre for Reviews and Dissemination (DARE, HTA, NHS EED). Results: A total of 11 economic evaluations were included. Methodological quality of included studies was acceptable. Scientific evidence shows that seasonal influenza vaccination programs in school-age children can be a cost-effective alternative from national health system perspective and can be cost-saving from societal perspective in European countries. However, available evidence does not allow us to conclude that influenza vaccination programs in healthy adults under 65 years of age were a cost-effective alternative in our context, due to the high uncertainty and the lack of studies carried out in Spanish context. Conclusions: Vaccination programs for the prevention of seasonal influenza in school-age children (3-16 years) can be a cost-effective strategy.
- Published
- 2018
22. Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review
- Author
-
Valcárcel Nazco, Cristina, García Lorenzo, Borja, Del Pino Sedeño, Tasmania, García Pérez, Lidia, Brito García, Noé, Linertová, Renata, Ferrer Rodríguez, Jorge, Imaz-Iglesia, Iñaki, and Serrano Aguilar, Pedro
- Subjects
Adult ,Aged, 80 and over ,Coste-efectividad ,Adolescent ,Influenza vaccine ,Cost-Benefit Analysis ,Vacuna de la gripe ,Gripe ,España ,Revisión sistemática ,Age Factors ,Middle Aged ,Influenza ,Europe ,Young Adult ,Spain ,Influenza Vaccines ,Child, Preschool ,Influenza, Human ,Systematic review ,Humans ,Cost-effectiveness ,Seasons ,Child ,Aged - Abstract
BACKGROUND: Given the economic burden of seasonal influenza for the healthcare system, we performed a systematic review aiming to update available evidence on the cost-effectiveness of vaccination of seasonal influenza in different age groups, including children. METHODS: A systematic review of the literature on economic evaluations of seasonal influenza vaccination programs in children and adults was carried out. The following databases were searched (January 2013 - April 2018): Medline and PREMEDLINE, EMBASE, Fundamentos: Dada la carga económica que supone para el sistema sanitario la gripe estacional, se plantea esta revisión sistemática cuyo ob-jetivo fue actualizar la evidencia disponible sobre el coste-efectividad de vacunación contra la gripe estacional en diferentes grupos de edad, inclu-yendo población infantil.Métodos: Se llevó a cabo una revisión sistemática de la literatura de evaluaciones económicas de los programas de vacunación contra la gripe estacional en niños y adultos. Se realizaron búsquedas en las bases de datos (enero 2013 – abril 2018): Medline y PREMEDLINE, EMBASE, EconLit y en las bases de datos del Centre for Reviews and Dissemination (DARE, HTA, NHS EED). Resultados: Se incluyeron 11 evaluaciones económicas. La calidad metodológica de los estudios incluidos fue buena. La evidencia científica muestra que los programas de vacunación contra la gripe estacional en niños en edad escolar pueden ser una estrategia coste-efectiva desde la perspectiva sanitaria en países europeos. La evidencia científica disponible hasta el mo-mento no nos permite concluir que los programas de vacunación antigripal en adultos sanos de menos de 65 años de edad sean una alternativa coste-efectiva en nuestro contexto, debido a la elevada incertidumbre existente y a la escasez de estudios realizados en el contexto español.Conclusiones: Los programas de vacunación contra la gripe estacional en niños en edad escolar (3-16 años) pueden ser una estrategia coste-efectiva desde la perspectiva del SNS. Palabras clave: Gripe, Vacuna de la gripe, Coste-efectividad, España, Revisión sistemáticEconLit and databases of the Centre for Reviews and Dissemination (DARE, HTA, NHS EED). RESULTS: A total of 11 economic evaluations were included. Methodological quality of included studies was acceptable. Scientific evidence shows that seasonal influenza vaccination programs in school-age children can be a cost-effective alternative from national health system perspective and can be cost-saving from societal perspective in European countries. However, available evidence does not allow us to conclude that influenza vaccination programs in healthy adults under 65 years of age were a cost-effective alternative in our context, due to the high uncertainty and the lack of studies carried out in Spanish context. CONCLUSIONS: Vaccination programs for the prevention of seasonal influenza in school-age children (3-16 years) can be a cost-effective strategy. Sí
- Published
- 2018
23. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain
- Author
-
García-Lorenzo, Borja, primary, Rivero-Santana, Amado, additional, Vallejo-Torres, Laura, additional, Castilla-Rodríguez, Iván, additional, García-Pérez, Sonia, additional, García-Pérez, Lidia, additional, and Perestelo-Pérez, Lilisbeth, additional
- Published
- 2018
- Full Text
- View/download PDF
24. Estimating a cost-effectiveness threshold for the Spanish NHS.
- Author
-
Vallejo‐Torres, Laura, García‐Lorenzo, Borja, Serrano‐Aguilar, Pedro, Vallejo-Torres, Laura, García-Lorenzo, Borja, and Serrano-Aguilar, Pedro
- Abstract
The cost of generating a quality-adjusted life year (QALY) within a National Health Service provides an approximation of the average opportunity cost of funding decisions. This information can be used to inform a cost-effectiveness threshold. The aim of this paper is to estimate the cost per QALY at the Spanish National Health Service. We exploit variation across 17 regional health services and the exogenous changes in expenditure that took place as a consequence of the economic crisis over 5 years of data. We conduct fixed effect models and use an instrumental variable approach to test for potential remaining endogeneity. Our results show that health expenditure has a positive and significant effect on population health, with an average spending elasticity of 0.07. This translates into a cost per QALY of between 22,000€ and 25,000€. These values are below the cost-effectiveness threshold figure of 30,000€ commonly cited in Spain. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Estimating a cost-effectiveness threshold for the Spanish NHS
- Author
-
Vallejo-Torres, Laura, primary, García-Lorenzo, Borja, additional, and Serrano-Aguilar, Pedro, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Evaluación económica busca umbral para apoyar la toma de decisiones
- Author
-
García-Lorenzo, Borja, Vallejo-Torres, Laura, Trujillo-Martín, María del Mar, Perestelo-Pérez, Lilisbeth, Valcárcel-Nazco, Cristina, and Serrano Aguilar, Pedro
- Subjects
Spain ,Evaluación económica ,Quality-Adjusted Life Year ,España ,Años de Vida Ajustados por calidad de vida ,Health technology assessment ,Evaluación de Tecnologías sanitarias ,Economic evaluation - Abstract
Para que la evaluación económica pueda ser incorporada en la toma de decisiones se debe conocer cuánto está dispuesto y es capaz de invertir por un Año de Vida Ajustado por Calidad (AVAC) el Sistema Nacional de Salud. En España se ha extendido el uso de 30.000€ por AVAC como umbral coste-efectividad (CE) pero, como en la mayoría de los sistemas sanitarios, no se ha adoptado un valor formalmente. Esto se debe en parte a la arbitrariedad, la falta de base teórica y científica para su fijación y la controversia que persiste sobre su estimación y lo que dicho umbral CE debe representar. A partir de una revisión sistemática de trabajos empíricos sobre la estimación del umbral CE realizada por este equipo investigador, se llevó a cabo una valoración crítica del estado del arte utilizando un grupo Delphi con la participación de 13 expertos nacionales. Este artículo contribuye a reflexionar cuánto se ha avanzado en investigación sobre el umbral CE en España, a considerar su utilidad para completar el proceso de toma de decisiones bajo evaluación económica, y a plantear líneas de investigación para mejorar lo logrado hasta la fecha. To incorporate economic evaluation into decision-making, we need to know how much a health system is willing and able to invest in a quality-adjusted life year (QALY). In Spain, the figure of €30,000 per QALY as cost-effectiveness (CE) threshold has been widely cited. However, as in most health systems, no value has been formally adopted; mainly because of the arbitrariness, the lack of theoretical and scientific basis, and the controversy around its estimation and what the threshold should represent. Based on a systematic review of empirical studies on the estimation of the CE threshold undertaken by this research team, we conducted a critical appraisal of the state of the art, using a Delphi with the participation of 13 national experts. This paper contributes to assess the research progress on the CE threshold in Spain, to consider its utility in the decision making process supported by economic evaluation, and to propose further research to improve what has been achieved so far.
- Published
- 2015
27. Modeling global pricing and launching of new drugs
- Author
-
García Lorenzo, Borja, González López-Valcárcel, Beatriz, and Departamento de Métodos Cuantitativos en Economía y Gestión
- Subjects
3209 Farmacología ,5312 Economía sectorial ,531211 Comercio - Abstract
Doctorado en Economía: Aplicaciones a las finanzas y seguros, a la economía sectorial, al medio ambiente y a las infraestructuras.
- Published
- 2014
28. Evaluación económica busca umbral para apoyar la toma de decisiones
- Author
-
García Lorenzo, Borja, Vallejo Torres, Laura, Trujillo Martín, María del Mar, Perestelo Pérez, Lilisbeth, Serrano Aguilar, Pedro, Valcárcel Nazco, Cristina, García Lorenzo, Borja, Vallejo Torres, Laura, Trujillo Martín, María del Mar, Perestelo Pérez, Lilisbeth, Serrano Aguilar, Pedro, and Valcárcel Nazco, Cristina
- Abstract
To incorporate economic evaluation into decision-making, we need to know how much a health system is willing and able to invest in a quality-adjusted life year (QALY). In Spain, the figure of 30,000 per QALY as cost-effectiveness (CE) threshold has been widely cited. However, as in most health systems, no value has been formally adopted; mainly because of the arbitrariness, the lack of theoretical and scientific basis, and the controversy around its estimation and what the threshold should represent. Based on a systematic review of empirical studies on the estimation of the CE threshold undertaken by this research team, we conducted a critical appraisal of the state of the art, using a Delphi with the participation of 13 national experts. This paper contributes to assess the research progress on the CE threshold in Spain, to consider its utility in the decision making process supported by economic evaluation, and to propose further research to improve what has been achieved so far., Para que la evaluación económica pueda ser incorporada en la toma de decisiones se debe conocer cuánto está dispuesto y es capaz de invertir por un Año de Vida Ajustado por Calidad (AVAC) el Sistema Nacional de Salud. En España se ha extendido el uso de 30.000 por AVAC como umbral coste-efectividad (CE) pero, como en la mayoría de los sistemas sanitarios, no se ha adoptado un valor formalmente. Esto se debe en parte a la arbitrariedad, la falta de base teórica y científica para su fijación y la controversia que persiste sobre su estimación y lo que dicho umbral CE debe representar. A partir de una revisión sistemática de trabajos empíricos sobre la estimación del umbral CE realizada por este equipo investigador, se llevó a cabo una valoración crítica del estado del arte utilizando un grupo Delphi con la participación de 13 expertos nacionales. Este artículo contribuye a reflexionar cuánto se ha avanzado en investigación sobre el umbral CE en España, a considerar su utilidad para completar el proceso de toma de decisiones bajo evaluación económica, y a plantear líneas de investigación para mejorar lo logrado hasta la fecha.
- Published
- 2015
29. Evaluación económica busca umbral para apoyar la toma de decisiones
- Author
-
García-Lorenzo, Borja, primary, Vallejo-Torres, Laura, additional, Trujillo-Martín, María del Mar, additional, Perestelo-Pérez, Lilisbeth, additional, Valcárcel-Nazco, Cristina, additional, and Serrano Aguilar, Pedro, additional
- Published
- 2015
- Full Text
- View/download PDF
30. Herramientas metodológicas para benchmarking en medicina basada en el valor: arquetipos y clasificación de pacientes
- Author
-
Otamendi Garitano, Maialen, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, ASOC Instituto de Investigación en servicios de salud, and García Lorenzo, Borja
- Subjects
Estadística matemàtica ,Mathematical statistics ,Cluster analysis ,Cáncer de mama ,Análisis de Clases Latentes ,Matemàtiques i estadística [Àrees temàtiques de la UPC] ,Medicina Basada en el Valor ,Clasificación ,Arquetipos ,Anàlisi de conglomerats ,62 Statistics::62G Nonparametric inference [Classificació AMS] - Published
- 2023
31. Monitorización prolongada video-eeg de pacientes remitidos por epilepsia refractaria en una unidad de epilepsia de un hospital terciario : efectividad clínica, evaluación económica e impacto presupuestario
- Author
-
Becerra Cuñat, Juan Luis, García-Lorenzo, Borja, Rocamora Zúñiga, Rodrigo Alberto, and Dávalos, Antoni
- Subjects
Epilèpsia refractaria ,Avaluació econòmica ,Monitorización video-eeg ,Evaluación económica ,Monitorització video-eeg ,Long term video-eeg monitoring ,Ciències de la Salut ,Epilepsia refractaria ,Refractory epilepsy ,Economic evaluation - Abstract
Introducció: La monitorització perllongada vídeo-EEG (MPVEEG) és la prova de certesa en el diagnòstic d’epilèpsia. La Comissió Europea recomana un centre amb MPVEEG i cirurgia cada 3.000 pacients amb epilèpsia refractària (ER). A Espanya 2019 existeix un centre acreditat cada 10.600 pacients amb ER. Objectius: Aquest estudi pretén analitzar l’ús de la MPVEEG vs. No MPVEEG en ER en termes de seguretat, efectivitat clínica, eficiència i viabilitat econòmica a Espanya. Material i Mètodes: Cohort prospectiva de pacients amb ER remesos per MPVEEG de novembre 2007 a maig 2017. El disseny de l’estudi va ser un abans-després comparant les variables abans i un any després de la MPVEEG. Seguretat: Es determinaren les complicacions mèdiques durant l’ingrés. Efectivitat clínica: Es compararen els pacients segons el diagnòstic de certesa després del estudi. Avaluació econòmica: Es realitzà un estudi econòmic comparant l’opció MPVEEG vs no MPVEEG, exclusivament amb fàrmacs anticrisi (FAES)mitjançant un anàlisi de cost-efectivitat amb un arbre de decisió juntament amb un model de Markov. Com a mesura d’efectivitat s’utilitzaren els anys de vida ajustats per qualitat (AVAQ). Impacte pressupostari: Es comparà l’escenari actual FAES i accés restringit a la MPVEEG (29,4%) amb un nou escenari assumint l’ús de la MPVEEG i les estratègies derivades en el total d’ER en un horitzó temporal de 6 anys. Resultats: Inclusió de 278 pacients amb seguiment a l’any. Seguretat: La taxa de complicacions mèdiques fou del 7,2%. S’observà una major probabilitat de complicacions en pacients amb major nombre de crisis (OR 1,04; 95% CI: 1,02-1,06, p = 0,002), amb cinc o més crisi amb una àrea sota la corba (ASC) de 0,76, p = 0,04 i amb dos o més crisi tònico-clòniques amb un ASC de 0, 77, p = 0,02 durant l’ingrés. Efectivitat: Es produí un canvi diagnòstic en el 46,9% i un canvi terapèutic en el 59,4% després MPVEEG. El grup de canvi en el diagnòstic presentà major reducció de crisi (p = 0,03), de fàrmacs (p = 0,001) i major millora en qualitat de vida (p = 0,006) a l’any enfront del grup sense canvis. Eficiència: El grup MPVEEG vs no MPVEEG, tingué un cost mitjà incremental de 17.472 Euros per pacient i una efectivitat de 8 AVACs, generant una ràtio de cost efectivitat incremental (RCEI) de 2.175 Euros per AVAQ, inferior al llindar cost efectivitat (llindar CE ) de 20.000 ? per AVAQ a Espanya. Les anàlisis de sensibilitat foren robustes a l’RCEI estimat. La probabilitat que la MPVEEG sigui una tecnologia CE vs. No MPVEEG d’acord amb el llindar CE a Espanya, és de el 100%. Impacte pressupostari: El primer any s’estimà en 841.933.705 euros pel conjunt d’ER a Espanya. Aquest impacte es reduí dràsticament en el segon any, a 83.241.594, per disminuir posteriorment de forma lleu. Conclusions La MPVEEG és una tecnologia sanitària segura, efectiva i eficient vs. No MPVEEG. Es recomana el seu finançament i implantació. El present estudi és pioner a Europa i la seva escalabilitat permet que pugui ser aplicable en economies similars a l’espanyola. Introducción: La monitorización prolongada video-EEG (MPVEEG) es la prueba de certeza en el diagnóstico de epilepsia. La Comisión Europea recomienda un centro con MPVEEG y cirugía cada 3.000 pacientes con epilepsia refractaria (ER). En España en 2019 existe un centro acreditado cada 10.600 pacientes con ER. Objetivos: Este estudio pretende analizar el uso de la MPVEEG vs. No MPVEEG en ER en términos de seguridad, efectividad clínica, eficiencia y viabilidad económica en España. Material y Métodos: Cohorte prospectiva de pacientes remitidos por ER para MPVEEG de noviembre 2007 a mayo 2017. El diseño del estudio fue un antes-después comparando las variables antes y un año tras la MPVEEG. Seguridad: Se determinaron las complicaciones médicas durante el ingreso. Efectividad clínica: Se compararon los pacientes según el diagnóstico de certeza tras la MPVEEG. Evaluación económica: Se realizó un estudio económico comparando la opción MPVEEG vs no MPVEEG, exclusivamente con fármacos anticrisis (FAES). Se realizó análisis de coste-efectividad mediante un árbol de decisión junto con un modelo de Markov, utilizando como medida de efectividad los años de vida ajustados por calidad (AVAC). Impacto presupuestario: Se comparó el escenario actual FAES y acceso restringido a la MPVEEG (29,4%) con un nuevo escenario asumiendo el uso de la MPVEEG y las estrategias derivadas en el total de ER en horizonte temporal de 6 años. Resultados: Se incluyeron 278 pacientes con seguimiento al año. Seguridad: La tasa de complicaciones médicas fue del 7,2%. Se observó una mayor probabilidad de complicaciones en pacientes con mayor número de crisis (OR 1,04; 95% CI: 1,02–1,06, p= 0,002), con cinco o más crisis con un área bajo la curva (ABC) de 0,76, p=0,04 y con dos o más crisis tónico-clónicas con un ABC de 0, 77, p=0,02 durante el ingreso. Efectividad: Se produjo cambio diagnóstico en el 46,9% y un cambio terapéutico en el 59,4% tras MPVEEG. El grupo de cambio en el diagnóstico presentó mayor reducción de crisis (p= 0,03), de fármacos (p= 0,001) y mayor mejoría en calidad de vida (p= 0,006) al año frente al grupo sin cambios. Eficiencia: El grupo MPVEEG vs no MPVEEG, presentó un coste medio incremental de 17.472 Euros por paciente y una efectividad de 8 AVACs, generando una ratio de coste efectividad incremental(RCEI) de 2.175 Euros por AVAC, inferior al umbral coste efectividad (umbral CE) de 20.000? por AVAC en España. Los análisis de sensibilidad fueron robustos al RCEI estimado. La probabilidad de que la MPVEEG sea una tecnología CE frente no MPVEEG de acuerdo con el umbral CE en España, es del 100%. Impacto presupuestario: El primer año se estimó en 841.933.705 Euros para el conjunto de ER en España. Este impacto se redujo drásticamente en el segundo año, a 83.241.594, para disminuir posteriormente de forma leve. Conclusiones La MPVEEG es una tecnología sanitaria segura, efectiva y eficiente vs. No MPVEEG. Se recomienda su financiación e implantación. El presente estudio es pionero en Europa y su escalabilidad permite que pueda ser aplicable en economías similares a la española. Introduction: Long-term video-EEG monitoring (LTVEEG-m) is the test of certainty in the diagnosis of epilepsy. The European Commission recommends one specialized center with LTVEEG-m and epilepsy surgery for every 3,000 patients with refractory epilepsy (RE). In Spain in 2019 there was one center accredited every 10,600 patients with RE. Objectives: This study aims to analyze the use of LTVEEG-m versus no LTVEEG-m in RE patients in terms of safety, clinical effectiveness, efficiency, and economic feasibility in Spain Material and Methods: Between November 2007 and May 2017, information was collected from a prospective cohort referred to LTVEEG-m. The design was a before-after study and a comparison of the variables before and one year after LTVEEG-m was performed. Safety: Medical complications during admission were performed. Clinical effectiveness: Patients were compared regarding the certainty diagnosis after LTVEEG-m. Economic evaluation: A full economic assessment of health outcomes and costs of LTVEEG-m vs. no LTVEEG-m, treatment based exclusively on antiepileptic drugs (ASD) were conducted. The cost-effectiveness analysis was implemented using a decision tree together a Markov model. Quality Adjusted Years of Life (QALY) were used as an effective measure. Budgetary impact: We compared the current scenario ASD and restricted access to LTVEEG-m (29.4%) with a new scenario that assumes the use of LTVEEG-m, and the strategies derived in all patients with RE for a horizon of six years. Results: 278 patients with one-year follow-up were included. Safety: The rate of medical complications was 7.2%. A higher likelihood of complications was observed in patients with a higher number of seizures (OR 1.04; 95% CI: 1.02–1.06, 0.002), with five or more seizures with an area under the curve (AUC) of 0.76 p-0.04 and with two or more tonic-clonic seizures with AUC of 0.77, p-0.02. Effectiveness: After LTVEEG-m a diagnostic change (46.9%) and a therapeutic change (59.4%) was determined. The group with a change in diagnosis showed a further reduction in seizure frequency (p- 0.03), in number of ASD ( p-0.001) and a greater improvement in quality of life (p-0.006) at one year compared to the group without changes. Efficiency: LTVEEG-m vs. no LTVEEG-m group, present an estimate average incremental cost of 17,472 Euros per patient and an incremental effectiveness of 8 QALY , generating a cost effectiveness ratio (ICER) of 2,175 Euros per QALY, lower than the cost effectiveness threshold (CE threshold) of 20,000 Euros per QALY in Spain. The sensitivity analysis offered robustness to the ICER. The probability that LTVEEG-m is a CE technology against no LTVEEG-m, according to the CE threshold in Spain, was 100%. Budgetary impact: The first year’s budget was estimated at 841,933,705 Euros for all patients with RE in Spain. This impact is reduced drastically to the second year at 83,241,594 Euros and it continues to be slightly reduced. Conclusions: LTVEEG-m is a safe, effective and efficient health technology compared to no LTVEEG-m. Its financing and implementation is recommended. This is a pioneering study in Europe, whose scalability allows its results to be considered in economies similar to the Spanish one. Universitat Autònoma de Barcelona. Programa de Doctorat en Medicina
- Published
- 2021
32. Performance of a rapid molecular test to detect Chlamydia trachomatis and Neisseria gonorrhoeae in women with pelvic inflammatory disease.
- Author
-
Munrós J, Vergara A, Bataller E, García-Lorenzo B, Álvarez-Martínez MJ, and Bosch J
- Abstract
Objective: The aim of this study was to investigate the prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in women with pelvic inflammatory disease (PID) and the usefulness and cost-effectiveness of a rapid molecular test for the diagnosis and clinical management of PID., Methods: This observational study included 75 patients with mild-to-moderate PID (n=33), severe PID (n=29) and non-specific lower abdominal pain (NSAP) (n=13). CT/NG infections were analyzed using a standard and a rapid test. A cost analysis was carried out., Results: Samples of 19 patients (25.3%) were CT/NG positive. Concordance between rapid and standard tests was 100%. No significant differences were observed in the incidence of CT/NG in mild-to-moderate compared to severe PID. Costs differed according only to disease severity., Conclusions: Rapid molecular tests could help with the diagnosis of PID in sexually active women in clinical settings in which a standard technique is not available., (Copyright © 2021 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. [Evaluation of programs to reduce alcohol consumption in Spain: a pending issue.]
- Author
-
García-Lorenzo B and Trapero-Bertran M
- Subjects
- Alcohol Drinking therapy, Health Promotion organization & administration, Humans, Outcome Assessment, Health Care, Program Evaluation, Public Health, Spain, Alcohol Drinking prevention & control, Health Promotion methods, Mental Health Services organization & administration
- Abstract
Objective: To evaluate preventive interventions on alcohol consumption has been long recommended in Spain. The impact evaluation of structured programs and specific actions for the prevention and treatment of alcohol consumption (PAPTCA) would allow making better informed decisions on public health financing based on the efficiency criteria. To the best of our knowledge, there is no scientific document that illustrates the situation of the PAPTCAs' evaluation in Spain. This paper aims to classify and describe PAPTCAs in Spain, focused on their impact evaluation and information on financing for accountability to society., Methods: A systematic literature review of the PAPTCAs implemented in Spain, from 2000 till 2017, at regional (autonomous communities) and local level was carried out, and a descriptive analysis of the PAPTCA database obtained from the literature review was carried out., Results: 145 structured programs and 45 specific actions were identified. Only 25% of structured programs provided an impact evaluation, besides, only 15% presented some information about their financing. Regarding the specific actions, the numbers were less encouraging where 10% provided an impact evaluation while a similar figure of PAPTCAs showed financing information., Conclusions: There is a need to systematize the information of the PAPTCA that serves as an instrument to conduct impact evaluations in Spain. This should ease the scarce presence of evaluative culture in this area and promote the accountability of resources spent on public health to society.
- Published
- 2020
34. Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic review
- Author
-
Valcárcel Nazco C, García Lorenzo B, Del Pino Sedeño T, García Pérez L, Brito García N, Linertová R, Ferrer Rodríguez J, Imaz Iglesia I, and Serrano Aguilar P
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Europe, Humans, Influenza, Human economics, Middle Aged, Seasons, Young Adult, Cost-Benefit Analysis, Influenza Vaccines economics, Influenza, Human prevention & control
- Abstract
Background: Given the economic burden of seasonal influenza for the healthcare system, we performed a systematic review aiming to update available evidence on the cost-effectiveness of vaccination of seasonal influenza in different age groups, including children., Methods: A systematic review of the literature on economic evaluations of seasonal influenza vaccination programs in children and adults was carried out. The following databases were searched (January 2013 - April 2018): Medline and PREMEDLINE, EMBASE, EconLit and databases of the Centre for Reviews and Dissemination (DARE, HTA, NHS EED)., Results: A total of 11 economic evaluations were included. Methodological quality of included studies was acceptable. Scientific evidence shows that seasonal influenza vaccination programs in school-age children can be a cost-effective alternative from national health system perspective and can be cost-saving from societal perspective in European countries. However, available evidence does not allow us to conclude that influenza vaccination programs in healthy adults under 65 years of age were a cost-effective alternative in our context, due to the high uncertainty and the lack of studies carried out in Spanish context., Conclusions: Vaccination programs for the prevention of seasonal influenza in school-age children (3-16 years) can be a cost-effective strategy.
- Published
- 2018
35. [Economic evaluation seeks threshold to support decision-making].
- Author
-
García-Lorenzo B, Vallejo-Torres L, Trujillo-Martín MM, Perestelo-Pérez L, Valcárcel-Nazco C, and Serrano Aguilar P
- Subjects
- Humans, Spain, Cost-Benefit Analysis, Decision Making, Health Care Costs, Quality-Adjusted Life Years
- Abstract
To incorporate economic evaluation into decision-making, we need to know how much a health system is willing and able to invest in a quality-adjusted life year (QALY). In Spain, the figure of 30,000 per QALY as cost-effectiveness (CE) threshold has been widely cited. However, as in most health systems, no value has been formally adopted; mainly because of the arbitrariness, the lack of theoretical and scientific basis, and the controversy around its estimation and what the threshold should represent. Based on a systematic review of empirical studies on the estimation of the CE threshold undertaken by this research team, we conducted a critical appraisal of the state of the art, using a Delphi with the participation of 13 national experts. This paper contributes to assess the research progress on the CE threshold in Spain, to consider its utility in the decision making process supported by economic evaluation, and to propose further research to improve what has been achieved so far.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.